News Conference News VIVA 2024 Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II L.A. McKeown November 06, 2024
News Conference News VIVA 2024 Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK L.A. McKeown November 05, 2024
News Conference News VIVA 2022 ‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups L.A. McKeown November 04, 2022
News Conference News VIVA 2022 TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years L.A. McKeown November 03, 2022
News Conference News VIVA 2021 EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions L.A. McKeown October 12, 2021
News Conference News VIVA 2021 Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI L.A. McKeown October 08, 2021
News Conference News VIVA 2021 Striking Racial Gaps Exist in Care for Peripheral Interventions, Registry Affirms L.A. McKeown October 07, 2021
News Conference News VIVA 2021 Vascular Care Falls Short Before Amputation for CLI: Medicare Analysis L.A. McKeown October 06, 2021
News Conference News VIVA 2020 BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia L.A. McKeown November 11, 2020
News Conference News VIVA 2019 Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions L.A. McKeown November 13, 2019
News Conference News VIVA 2019 Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee? L.A. McKeown November 06, 2019
News Conference News VIVA 2018 Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease L.A. McKeown November 15, 2018